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Abstract
Background & Aims—Fluoroquinolone-induced liver injury is rare; no prospective studies of
well-characterized case series have been published. We studied patients with fluoroquinolone-
induced hepatoxicity, using data from the Drug-Induced Liver Injury Network (DILIN) to
characterize injury patterns, outcomes, and associated features.
Methods—We identified subjects with fluoroquinolone hepatotoxicity who enrolled in the
DILIN from September 2004 to January 2010. Demographic, clinical, and laboratory data were
analyzed by descriptive statistical methods.
Results—Of the 679 registrants in the DILIN prospective study, 12 had hepatoxicity from
fluoroquinolones (6 ciprofloxacin, 4 moxifloxacin, 1 levofloxacin, and 1 gatifloxacin). Seven were
women; the median age was 57 years (range 23–80 years), and the median time from the start of
fluoroquinolone therapy to symptoms was only 4 days (range 1–39 days). Nine cases developed
symptoms on medication (2, 8, and 32 days after they stopped the medication, 3 patients each).
Cases were equally distributed among hepatocellular injury (predominantly increased levels of
alanine aminotransferase), cholestatic injury (predominantly increased levels of alkaline
phosphatase [AP]), and both. Seven cases had immunoallergic features. Patients with mixed
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hepatocellular and cholestatic injury had mild disease without jaundice—all recovered. In contrast,
2 of 4 patients with hepatocellular injury and jaundice died, 1 of acute liver failure. One patient
with cholestatic injury developed vanishing bile duct syndrome and required liver transplantation;
another had a persistently increased serum level of AP.
Conclusions—Fluoroquinolone liver injury is rapid in onset and often has immunoallergic
features, indicating a hypersensitivity reaction. The pattern of injury is can be hepatocellular,
cholestatic, or mixed—mixed cases are the least severe. Acute and chronic liver failure can occur.
Keywords
ALT; drug toxicity; side effect; antibiotics; adverse reaction
INTRODUCTION
Fluoroquinolones are among the most widely prescribed antibiotics. They are popular
because of their high oral bioavailability, ease of dosing and broad antimicrobial coverage.
(1–5) They have been recommended as empiric antibiotic therapy in national guidelines.(6,
7) Severe side effects from the fluoroquinolones are uncommon, but include tendon rupture,
hemolytic uremic syndome, Stevens-Johnson syndrome, interstitial nephritis, arrhythmias,
and drug-induced liver injury (DILI).(8–12) In a recent publication of DILI from the United
States, the fluoroquinolones were among the most common causes of idiosyncratic acute
liver injury.(9) Fatal instances of hepatic injury from fluoroquinolones have been described.
Although there have been multiple case reports of hepatotoxicity from the fluoroquinolones,
there have been no larger reports even from large referral centers.(13–31) An exception is
trovafloxacin, a third generation fluoroquinolone, which was the subject of an FDA public
health advisory (32) and was subsequently withdrawn from the market as a result of
numerous cases of liver injury.(33–35)
In 2003, the NIDDK established the Drug-Induced Liver Injury Network (DILIN) (36) to
gather and characterize cases of DILI both prospectively (all herbals and medications except
acetaminophen) and retrospectively for selected medications. The DILIN registry continues
to enroll across 8 geographically dispersed U.S. centers. Subjects are interviewed for clinical
information, and blood samples are collected with the aim of identifying genetic and other
biochemical markers that may increase our understanding, diagnosis, and treatment of drug-
induced liver injury. The study design and methods have been reported (37) as have results
of the first 300 cases.(9) In this report, we describe our prospectively enrolled subjects with




The study design of the DILIN prospective study has been described.(9, 37) Briefly, patients
aged 2 or older were enrolled on the basis of clinical suspicion of liver injury due to a
medication or herbal product within 6 months of clinical onset. Inclusion criteria included
aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels > 5 times the
upper limit of normal (ULN) (or pretreatment baseline if abnormal) on 2 consecutive
occasions, or alkaline phosphatase (AP) levels > twice the ULN (or pretreatment baseline if
abnormal) on 2 consecutive occasions, or total serum bilirubin > 2.5 mg/dL (with elevated
AST, ALT, or AP), or international normalized ratio (INR) > 1.5 (with elevated AST, ALT,
or AP). A variety of tests are obtained at enrollment including serologies for acute hepatitis
A, B, CMV and EBV. Hepatitis C antibody tests are also obtained with confirmatory HCV
Orman et al. Page 2













RNA as necessary. Autoimmune markers (ANA, ASMA, AMA) and abdominal imaging
(ultrasound, CT or MRI) are also required. Patients with suspected acetaminophen
hepatotoxicity were excluded as were those with a liver or bone marrow transplant. Patients
with chronic hepatitis B or C or with nonalcoholic fatty liver disease were eligible for
enrollment, but those with other chronic liver diseases (such as alcoholic, autoimmune or
genetic liver diseases) were excluded.
Enrolled patients were seen for a baseline study visit at which time a detailed history was
obtained by a DILIN investigator, and clinical, laboratory, and imaging results were
extracted from the chart. These enrollment visits often took place days or weeks (up to 24
weeks) after initial clinical presentation. Further laboratory testing to exclude other causes of
liver injury were obtained and serum, plasma, urine and DNA specimens were collected for
future mechanistic studies. Attempts were made to follow all subjects for at least 6 months
after enrollment and those with persistent liver-related abnormalities were asked to return at
12 and 24 months.
Causality
The method for assigning causality has been described in detail.(38) Each case was
evaluated by 3 hepatologists including the site investigator who enrolled the case. Each
evaluator independently assigned a subjective score representing percentage likelihood of
attribution in which 1 = definite or > 95% likelihood, 2 = very likely or 75–95%, 3 =
probable or 50–74%, 4 = possible or 25–49%, and 5 = unlikely or < 25%. When there were
discrepancies, a consensus score was achieved after e-mail or conference call discussions.
Cases which were still in disagreement were voted upon by one member from each center
with the final score assigned by majority vote.(37, 39–41)
Participants
This study was based upon all subjects that had a fluoroquinolone suspected of causing DILI
prospectively enrolled and adjudicated by February 2010. The analysis was limited to cases
that were considered definite or highly likely. Cases considered probable were included only
if no other agent was implicated or suspected (i.e. single-agent case).
Data and Outcomes
Demographic, clinical history and laboratory results entered into the database were analyzed
with special attention to time course of DILI, latency, severity, type of reaction, associated
symptoms, resolution, chronic enzyme elevation, need for transplant and death. The pattern
of hepatic injury was categorized as hepatocellular, cholestatic, or mixed based upon the R-
ratio of serum ALT and AP elevation (39): R-ratio = [ALT value/ALT upper limit of
normal]/[AP value/AP upper limit of normal]. R-ratios of > 5 were considered
hepatocellular, < 2 cholestatic, and 2–5 mixed.(39) Standard descriptive statistics were
applied to continuous variables.
Liver biopsy was not required for enrollment in DILIN. Biopsies done for clinical
management were obtained and evaluated in a standardized fashion by the DILIN liver
histopathologist (DEK). Instructive histology from this cohort were chosen for this report.
Role of Funding Source and Institutional Board Review (IRB)
The DILIN Network is structured as a U01 cooperative agreement with funds provided by
the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Separate
IRB approvals were obtained at each participating DILIN center.
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Among 679 cases enrolled in the DILIN database which had undergone causality assessment
by February 2010, fluoroquinolones were listed as a potential cause in 30. In 15 cases the
fluoroquinolone was the only implicated drug, of which 3 were considered definite, 4 very
likely, 3 probable, and 5 were considered only possible or unlikely. Only the 10 single drug
cases that were considered definite, very likely or probable were included in this study.
Among the other 15 cases in which fluoroquinolones were one of several implicated agents,
none were considered definite and 2 were considered very likely with the other competing
drugs scoring only possible (metronidazole) or unlikely (amoxicillin/clavulanate). Only
these two cases that were considered very likely due to the fluoroquinolone were included in
the study bringing the total to 12. Thus, 12 of the 30 cases met all inclusion criteria, with 6
due to ciprofloxacin, 4 moxifloxacin, 1 levofloxacin, and 1 gatifloxicin.
Clinical Characteristics and Onset of Injury
Characteristics of the 12 cases are shown in Table 1. All were adults, and all except one
were over 30 years of age. The median age was 57 years, and 7 were women. Jaundice,
nausea and abdominal pain were frequent presenting symptoms. Overall, the time to liver
injury was short and the onset abrupt. Median time from starting the medication to earliest
sign or symptom of DILI was 4 days (range 1 to 39 days) and median time to documented
onset (abnormal liver tests) was 8.5 days (range 1 to 41 days). Median time to either was
only 2.5 days. Nine of the patients developed symptoms while still taking the antibiotic; the
remaining 3 became symptomatic 2, 8, and 32 days after stopping the fluoroquinolone. Two
patients had pre-existing nonalcoholic fatty liver disease (NAFLD), but no patient had
chronic hepatitis B or C. Diabetes and heart disease were common, 5/12 (42%) and 4/12
(33%) respectively.
Patterns of Injury
Patterns of injury by enrollment R-ratio and peak enzymes and bilirubin are shown in Table
2. All patients were symptomatic, 7 developed jaundice (defined as total serum bilirubin >
2.5 mg/dL), 8 were hospitalized for the DILI, 3 developed symptoms or signs of hepatic or
other organ failure, one ultimately required liver transplantation, and one died of liver
failure. The patterns of enzyme elevations were evenly distributed among cholestatic (n=4),
hepatocellular (n=4) and mixed (n=4) categories. The pattern of injury by calculated R-ratio
tended to remain constant during the acute course and the peak of illness, although a few
transitioned becoming more cholestatic during follow up. Mixed cases tended to have less
severe injury with lower bilirubin, ALT and AP levels. Cases with predominantly
hepatocellular injury were often severe; 2 of the 4 cases resulted in death within 6 months
(one known to be due to acute liver failure and the second due to death at home, not fully
explained by acute liver failure). The 4 cholestatic cases did not result in death, but two
developed chronic injury, one with histologically verified vanishing bile duct syndrome
requiring liver transplantation 1 year after presentation. The other had persistent elevations
in serum AP (200 U/L) without jaundice or pruritus 17 months after the injury. One other
patient with a cholestatic pattern of injury recovered to normal liver enzymes by 206 days.
The fourth case had falling liver enzymes (peak AP 837 down to 538 U/L, peak ALT 823 to
67 U/L) by 40 days post-injury, but thereafter he was lost to follow-up. In contrast, patients
with a mixed pattern of serum enzyme elevations tended to have less severe injury with
lower peak bilirubin (none were jaundiced), AP and ALT levels and shorter time from
enzyme elevation to return to normal (37 to 81 days).
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Three representative cases are shown in the Figures 1, a-c. Figure 1a shows the course of
serum enzyme and bilirubin levels in a patient with a hepatocellular pattern of injury (Case
12 in Table 2) occurring 18 days after starting ciprofloxacin. She developed acute liver
failure but was not a suitable transplant candidate at age 80 with multiple co-morbidities.
She was transferred to hospice care and died 4 weeks after initial elevation of ALT. Figure
1b shows a patient with a mixed pattern of enzyme elevation and self-limiting course (Case
7 in Table 2), arising 7 days after starting a course of levofloxacin with near complete and
complete resolution at 4 and 8 weeks, respectively. Figure 1c shows a patient with a
cholestatic pattern of serum enzyme elevations and prolonged, severe cholestasis arising 8
days after starting a course of moxifloxacin (Case 3 in Table 2). She developed prolonged
jaundice (1.3 years) ultimately leading to hepatic failure and liver transplantation with
histology of the explanted liver showing vanishing bile duct syndrome (Figure 2d).
Immunoallergic Features and Other Drug Allergies (Table 3)
Seven of the 12 had fever, rash and/or eosinophilia. Three patients had a positive ANA or
ASMA without other immunoallergic features. Since patients were enrolled up to 24 weeks
after the event, transient eosinophilia at the time of onset may have been missed. Fever was
reported more often in cholestatic pattern of injury. Rash occurred in patients with both high
and low R-ratios, but not in cases with a mixed pattern of enzyme elevations.
Hypersenstivity pneumonitis, Stevens-Johnson Syndrome and bone marrow suppression
were also seen. Seven of 12 patients had a history of allergy to other medications including
one patient who had separate hepatoxicity events after taking two different
fluoroquinolones.
Histology
Liver tissue was available for central review in 5 cases: four needle biopsies obtained during
the DILI episode and one explant. Three of the needle biopsies were from patients with a
predominantly hepatocellular biochemical injury. Two of these showed acute hepatitis with
lobular disarray and severe portal and lobular inflammation (Fig. 2a). One of these two had
striking hepatocyte giant cell transformation. The third case showed a mixed pattern of
injury with zone 3 coagulative necrosis and a distribution of inflammation reminiscent of
chronic hepatitis. In this case there was less lobular inflammation and no disarray, but dense
portal inflammation and interface hepatitis were present in most portal areas. Although all
three of these patients had jaundice, there was little-to-no cholestasis or duct injury on
biopsy. Two of the cases, including a needle biopsy and the explant, were from patients with
cholestatic presentations (Fig 2b–d). The needle biopsy showed a cholestatic hepatitis with
mild intrahepatic cholestasis and mild to moderate portal and lobular inflammation (Fig. 2b–
c). As noted above, the explant showed severe ductopenia and only mild inflammation (Fig.
2d). By the time of transplant most of the hepatocyte parenchyma had been replaced by a
ductular reaction embedded in dense fibrosis. Although these cases showed diverse patterns
of injury histologically, all four of the needle biopsies showed increased numbers of
eosinophils. Two (one hepatocellular and one cholestatic) showed increased numbers of
plasma cells in the infiltrate.
DISCUSSION
Hepatotoxicity from fluoroquinolones has been described in multiple case reports and
summarized in several reviews. However there are no well-characterized and prospectively
followed groups of cases published on hepatic injury from this important class of antibiotics.
The 12 cases presented here confirm that hepatic injury from the fluoroquinolones has a
“class effect” and the clinical presentation and phenotype of injury is similar with the
different agents. The predominant feature of the hepatic injury was the short latency (median
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2 to 9 days) and abrupt onset of injury (Table 1). Nine of our 12 cases developed symptoms
while still taking the antibiotic. Immunoallergic features (rash, fever and eosinophilia) were
common (Table 3), but rarely as prominent as occurs with hepatotoxicity from
sulfonamides, macrolides, or aromatic anticonvulsants. Only one of the 12 patients had
“DRESS syndrome” (drug rash with eosinophilia and systemic symptoms), a 45 year old
patient who developed Stevens-Johnson syndrome 7 days after starting a 10 day course of
ciprofloxacin. Six other patients had fever or rash, but eosinophilia was uncommon, perhaps
because the pattern of referral of patients to DILIN often resulted in a delay of a few weeks
before enrollment (by which time the eosinophil count might have normalized).
Immunoallergic features have been described in several case reports of fluoroquinolone
hepatotoxicity.(15, 21, 27, 30, 31)
The pattern of enzyme elevations described here varied greatly. Indeed, the full range of
clinical patterns was seen from very cholestatic cases with high AP (603 U/L) and high
bilirubin (33.4 mg/dL) that led to prolonged jaundice and vanishing bile duct syndrome
(Case 3, Table 2 and Figure 2d;), to obvious hepatocellular injury with high ALT (1684 U/
L) that led rapidly to hepatic failure and death (Case 12, Table 2 and Figure 2a). In between
these extremes were 6 cases without jaundice, 4 of which had a “mixed” pattern of serum
enzyme elevations and a self-limited, benign course (Cases 5–8, Table 2).
The pathophysiology of fluoroquinolone hepatotoxicity is not known. The short latency,
frequent immunoallergic features, heightened injury that has been described upon re-
exposure, and the lack of a common pattern of metabolism of the various fluoroquinolones
argue for a hypersensitivity reaction.(42) All four of our subjects with available liver
histology showed increased eosinophils and two had increased plasma cells. It has been
postulated that the trifluorinated quiniolones with their 1-(2,4)-difluorophenyl group may
carry an even greater risk for severe immune-mediated toxicities (e.g. temafloxacin
syndrome and trovafloxacin hepatotoxicity).(8) Interestingly, one half of our cases had a
history of allergies to non-fluoroquinolone medications suggesting increased susceptibility
in such individuals (Table 3). The immunoallergic phenotype makes it advisable for patients
with hepatotoxicity from one fluorquiniolone to avoid this class of antibiotic altogether.(43)
Indeed, one of our cases (Case 8, Table 3), had repeated reactions to two different
fluoroquinolones prescribed for recurrent diverticulitis. She was enrolled during a reaction
to ciprofloxacin. On follow-up, she had yet another reaction when she was given
levofloxacin (ALT up 1680 IU/L).
While our study is small, the cases were prospectively enrolled, and followed under
protocol. Therefore the quality of data on our subjects is likely higher than the average case
reports in the literature. In fact, our 12 cases contained the vast majority (>95%) of the 19
“Minimal Elements” suggested for DILI case reporting (Supplement Table 1).(44) Only 5 of
the 12 had had no liver tests checked prior to initiation of the fluoroquinolone and 6 did not
require a liver biopsy.
Attribution was made by expert opinion process, the gold standard for assigning DILI
causality. While we set out to enroll cases of at least probable attribution, the majority of our
qualifying cases actually had scored better than probable. In the DILIN, definite cases have
no other remotely possible causes and a pattern of injury that is stereotypic for the agent
based on previously described reports or papers in the literature. Thus the bar for being
considered definite (>95% likelihood) is high. Very likely cases also have high attribution,
but do not quite meet definite criteria. Therefore, 9 of 12 (75%) cases were highly
attributable to the fluoroquinolone scoring definite or very likely. Cases 5 and 12 were the
only two with competing agents and both were considered to be very likely due to the
fluoroquinolone. In case 5, amoxicillin/clavulanate was taken for just one day starting the
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day of the reaction and was therefore deemed an unlikely culprit. Metronidazole was a
competing agent in case 12 and was deemed only possible based on its low risk for DILI.
The three probable cases had no other competing agents.
Of the 7 fluoroquinolones that were available in the United States during the study period, 4
(ciprofloxacin, levofloxacin, moxifloxicin, and gatifloxacin) were represented in our study.
Gatifloxacin has since been withdrawn from the market due to problems with glucose
homeostasis. While our study did not include ofloxacin and norfloxacin, each has been
reported to cause hepatoxicity with similar injury patterns to those described here. (27, 45–
48) There are no cases of gemifloxicin hepatotoxicity reported, but it is relatively new and
animal studies suggest its potential to cause liver injury as well.(49) In addition, there are
several other fluoroquinolones available outside the US (Supplement Table 2), but little is
known about their risk for hepatotoxicity.
Estimates of hepatotoxicity incidence are hampered by biases and poor quality of reporting.
Package insert information suggests asymptomatic, mild and reversible elevations in liver
enzymes may occur in 2–3% of patients taking fluoroquinolones, (50) while a population-
based study from England suggested that the incidence of illness due to hepatotoxicity is
0.54 per 10,000 persons taking ciprofloxacin.(51) Estimate of “acute liver injury” from all
fluoroquinolones in Sweden is 0.7 per 100,000 users.(4) The predominance of ciprofloxacin
in our study probably reflected market share more than increased risk, but moxifloxacin
(incriminated in 4 cases) was probably over-represented. From 1996 to 2001, the number of
prescriptions written in the US was 66 million for ciprofloxacin, 24 million for levofloxacin,
3 million for gatifloxacin and 1 million for moxifloxacin.(50)
Acute liver failure rates are also difficult to ascertain, but estimates are quite low. From
2008 pharmacy data in the United States, levofloxacin, moxifloxacin and gatifloxacin have
similar rates of acute liver failure: 2.1, 6.6 and 6.1 cases per 10 million prescriptions,
respectively.(4) In contrast, trovafloxacin, which was withdrawn from use in the United
States in 1999 for hepatotoxicity, had a higher estimated rate of 58 per 10 million
prescriptions. By comparison, amoxicillin-clavulanate has a rate of 10 per 10 million.(4)
While rare, it is important to stress that liver injury from the fluoroquinolones can be severe
causing prolonged jaundice, morbidity and acute and chronic liver failure resulting in death
or transplant. Patients with fluoroquinolone-induced liver injury should be cautioned to
avoid re-exposure to other fluoroquinolones in the future and be informed that some brand
names do not intuitively imply the fluoroqinolone class (e.g. Avelox, Factive, Cravit). Since
there are no established means of preventing hepatotoxicity from the fluoroquinolones, it is
important to prescribe them for clear clinical indications only and to take a careful history of
drug allergies. Therapies for DILI are limited. Patients with prominent features of
hypersensitivity may improve with use of corticosteroids, but these agents should not be
used in cases without these features. N-acetylcysteine has been shown to improve
“transplant-free survival” in patients with non-acetominophen acute liver failure,
particularly those with drug-induced liver injury with early hepatic encephalopathy.(52)
Finally, all cases of drug-induced liver injury should be reported to national registries
whenever possible. In the United States, cases are reported to the FDA through MedWatch
(http://www.fda.gov/Safety/MedWatch/default.htm).
Thus, fluoroquinolones are highly effective and widely used antibiotics that rarely cause
clinical hepatotoxicity and even more rarely cause life-threatening liver injury. The clinical
phenotype of hepatotoxicity appears to be shared by all of the fluoroquinolones and is
characterized usually by a short period of latency and abrupt onset with features of
hypersensitivity. Some fluoroquinolones may carry a higher risk than others. Most patients
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with fluoroquinolone-associated hepatotoxicity recover, but the period of illness can be
prolonged, can result in hepatic failure and death or need for liver transplantation.
Ultimately, prevention and management of fluoroquinolone hepatotoxicity will require a
better understanding of its pathogenesis which provides the rationale for collection of well-
characterized cases of this rare condition for metabolic, immunologic and genetic study: the
primary aim of the DILIN network.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Serum ALT, AST, AP and bilirubin over time after 3 different fluoroquinolone induced liver
injuries. Expert opinion causality scores for all three cases were 2, or very likely. (a)
Ciprofloxacin induced hepatocellular injury causing acute liver failure and death. (b)
Levofloxacin induced mixed hepatocellular-cholestatic injury with recovery. (c)
Moxifloxicin induced cholestatic liver injury leading to prolonged cholestasis, ductopenia
and liver failure requiring transplant.
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Represent histopathology of three cases of fluoroquinolone induced liver injuries. (a) acute
hepatitis with giant cell transformation (arrows) during hepatocellular injury, (b) cholestatic
hepatitis showing mild zone 3 cholestasis (arrows), (c) mild portal inflammation with
plasma cells (black arrows) and scattered eosinophils (red arrows) during cholestatic injury,
and (d) vanishing bile duct syndrome after cholestatic injury (All hematoxylin and eosin
stains, 400x, 200x, 600x and 400x magnification respectively).
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Table 1
Clinical Characteristics of Fluoroquinolone Liver Injury Cases (n = 12)
Age in yrs., median (min., max.) 57 (23.6, 80.9)
Gender 7/12 women (58%)
Race (self-report)
 White 6/12 (50%)
 Black 3/12 (25%)
 Other 2/12 (17%)
 Unknown 1/12 (8%)
Latino 1/12 (8%)
Concurrent alcohol 4/12 (33%)
Body Mass Index, kg/m2, mean (std. dev.) 26.8 (3.67)
Latencies, median days (min, max)
 Drug start to symptoms 4.0 (1, 39)
 Drug start to DILI onset* 8.5 (1, 41)
 Drug start to symptoms or DILI onset* 2.5 (1, 39)
Signs and symptoms
 Jaundice 5/12 (42%)
 Nausea 7/12 (58%)
 Fever 5/12 (42%)
 Abdominal pain 7/12 (58%)
 Rash^ 6/12 (50%)
 Pruritus 7/12 (58%)
*
ALT > 5x ULN or AP > 2x ULN on two consecutive testings
^
one case of Stevens Johnson
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